ABOS vs. CMPX, ZURA, AGEN, OVID, IPHA, OPT, INMB, CHRS, IPSC, and KOD
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Compass Therapeutics (CMPX), Zura Bio (ZURA), Agenus (AGEN), Ovid Therapeutics (OVID), Innate Pharma (IPHA), Opthea (OPT), INmune Bio (INMB), Coherus BioSciences (CHRS), Century Therapeutics (IPSC), and Kodiak Sciences (KOD). These companies are all part of the "medical" sector.
Acumen Pharmaceuticals (NASDAQ:ABOS) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
Compass Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Acumen Pharmaceuticals currently has a consensus target price of $12.00, indicating a potential upside of 220.00%. Compass Therapeutics has a consensus target price of $9.00, indicating a potential upside of 469.62%. Given Compass Therapeutics' higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Acumen Pharmaceuticals.
Acumen Pharmaceuticals has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
In the previous week, Compass Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 21 mentions for Compass Therapeutics and 20 mentions for Acumen Pharmaceuticals. Compass Therapeutics' average media sentiment score of 0.77 beat Acumen Pharmaceuticals' score of 0.47 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Compass Therapeutics received 5 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 72.73% of users gave Compass Therapeutics an outperform vote while only 65.52% of users gave Acumen Pharmaceuticals an outperform vote.
Acumen Pharmaceuticals' return on equity of -22.88% beat Compass Therapeutics' return on equity.
Summary
Compass Therapeutics beats Acumen Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
